Oppenheimer Reiterates Outperform on DiaMedica Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on DiaMedica Therapeutics (NASDAQ:DMAC) and maintained a $6 price target.
August 16, 2024 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on DiaMedica Therapeutics and maintained a $6 price target.
The reiteration of an Outperform rating and the maintenance of a $6 price target by a reputable analyst can boost investor confidence in DMAC, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100